Comparative Pharmacology
Head-to-head clinical analysis: PHENURONE versus PROMPT PHENYTOIN SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PHENURONE versus PROMPT PHENYTOIN SODIUM.
PHENURONE vs PROMPT PHENYTOIN SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phenurone (phenacemide) is an anticonvulsant that reduces neuronal excitability by inhibiting voltage-gated sodium channels and potentiating GABAergic inhibition. It also has a structure similar to other hydantoins and may increase the seizure threshold.
Phenytoin stabilizes neuronal membranes by promoting sodium channel inactivation, thereby reducing repetitive firing of action potentials and inhibiting the spread of seizure activity.
Adults: 500 mg to 1 g orally twice daily, increased gradually up to 3 g/day in divided doses.
Loading dose: 15-20 mg/kg (max 1500 mg) IV at a rate not exceeding 50 mg/min. Maintenance dose: 300-600 mg/day IV or orally in 3 divided doses. Adjust per therapeutic drug monitoring (target total phenytoin 10-20 mcg/mL).
None Documented
None Documented
The terminal elimination half-life is approximately 22-35 hours in adults. This long half-life supports once- or twice-daily dosing, but requires careful monitoring for accumulation.
30-100 hours (average 40 hours) following IV administration; prolonged in hepatic impairment, neonates, and with enzyme inhibitors; shorter in children and with enzyme inducers.
Phenurone is extensively metabolized in the liver; less than 1% is excreted unchanged in urine. The primary metabolite is 4-hydroxyphenylethylhydantoin (p-HPEH). Renal excretion accounts for approximately 70-80% of the dose, mainly as metabolites; the remainder is eliminated via bile/feces. Enterohepatic circulation may occur.
Primarily hepatic metabolism (CYP2C9) to inactive p-HPPH. Renal excretion as p-HPPH glucuronide (~60-70%) and unchanged drug (5%), with ~30% biliary/fecal elimination.
Category C
Category D/X
Anticonvulsant
Anticonvulsant